Sign in
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
2 Real-World Analyses of Treatment Burden Associated With Intravitreal Injections for DME Prior to 0.2 mcg/Day Fluocinolone Acetonide (FAc)
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2018
Methotrexate Bubble following Intravitreal Injection for PVR
Zach Seim
Retina Image Bank: Images of the Week
2022
Category: Instrumentation and Devices